AAB
VRTX icon

ABN AMRO Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

ABN AMRO Bank’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.5M Buy
125,970
+7,621
+6% +$3.38M 0.81% 38
2026
Q1 		$53.3M Sell
118,349
-36,872
-24% -$17.2M 0.57% 39
2025
Q4 		$70.1M Buy
155,221
+13,350
+9% +$5.75M 0.66% 38
2025
Q3 		$55.4M Buy
141,871
+8,799
+7% +$3.68M 0.54% 40
2025
Q2 		$59.6M Buy
133,072
+5,679
+4% +$2.62M 0.78% 30
2025
Q1 		$61.7M Buy
127,393
+3,341
+3% +$1.56M 0.85% 31
2024
Q4 		$49.5M Buy
124,052
+7,383
+6% +$3.42M 0.67% 36
2024
Q3 		$53.8M Buy
116,669
+3,150
+3% +$1.51M 0.74% 34
2024
Q2 		$53.7M Buy
113,519
+2,178
+2% +$945K 0.81% 30
2024
Q1 		$46.6M Buy
111,341
+7,127
+7% +$3.01M 0.7% 32
2023
Q4 		$42.6M Buy
104,214
+7,473
+8% +$2.76M 0.7% 33
2023
Q3 		$33.6M Buy
96,741
+2,010
+2% +$703K 0.61% 34
2023
Q2 		$33.4M Buy
94,731
+1,737
+2% +$585K 0.68% 30
2023
Q1 		$29.3M Buy
+92,994
New +$27.9M 0.65% 30

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ABN AMRO Bank's VRTX Position: Q2 2026 in Review

ABN AMRO Bank increased its Vertex Pharmaceuticals (VRTX) stake by 6.4% in Q2 2026, buying an estimated $3.38M and bringing the position to 125,970 shares worth $62.5M. The position accounts for 0.81% of the portfolio, ranked #38.

ABN AMRO Bank first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $70.1M in Q4 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • ABN AMRO Bank held 125,970 shares of Vertex Pharmaceuticals worth $62.5M as of Q2 2026.
  • ABN AMRO Bank bought 7,621 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.38M.
  • Vertex Pharmaceuticals made up 0.81% of ABN AMRO Bank's portfolio in Q2 2026, its #38 holding.
  • ABN AMRO Bank first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • ABN AMRO Bank's Vertex Pharmaceuticals position peaked at $70.1M in Q4 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on ABN AMRO Bank's 13F filing for Q2 2026, filed 6 Aug 2026.